<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396730</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00020906</org_study_id>
    <nct_id>NCT04396730</nct_id>
  </id_info>
  <brief_title>Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction</brief_title>
  <official_title>Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess how Cannabidiol (CBD) impacts the effectiveness of
      oral contraceptive (birth control) pills and if CBD changes the possible side effects of
      birth control pills when CBD and birth control pills are taken at the same time.

      This study explores the potential interaction between CBD and birth control pills by
      assessing serum levels of the contraceptive steroid hormones ethinyl estradiol and
      levonorgestrel in birth control pill users when they also use CBD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration Ethinyl Estradiol</measure>
    <time_frame>At the end of Cycle 1 and 3 (each cycle is 28 days)</time_frame>
    <description>Area under the plasma concentration vs time curve of ethinyl estradiol (EE) with and without concomitant CBD administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration of Levonorgestrel</measure>
    <time_frame>At the end of Cycle 1 and 3 (each cycle is 28 days)</time_frame>
    <description>Area under the plasma concentration vs time curve of levonorgestrel (LNG) with and without concomitant CBD administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum measured plasma concentration (Tmax)</measure>
    <time_frame>At the end of Cycle 1 and 3 (each cycle is 28 days)</time_frame>
    <description>Time to maximum measured plasma concentration of LNG and EE. (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum measured plasma concentration (Cmax)</measure>
    <time_frame>At the end of Cycle 1 and 3 (each cycle is 28 days)</time_frame>
    <description>Time to maximum measured plasma concentration of LNG and EE (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final time taken for plasma concentration to be reduced by half (t1/2)</measure>
    <time_frame>At the end of Cycle 1 and 3 (each cycle is 28 days)</time_frame>
    <description>Final time taken for plasma concentration of LNG and EE to be reduced by half (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma concentration of LNG and EE vs. time curve (AUC)</measure>
    <time_frame>At the end of Cycle 1 and 3 (each cycle is 28 days)</time_frame>
    <description>The area under the plasma concentration of LNG and EE vs. time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The first-order final elimination rate constant of EE and LNG</measure>
    <time_frame>At the end of Cycle 1 and 3 (each cycle is 28 days)</time_frame>
    <description>The first-order final elimination rate constant of EE and LNG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Placebo + OCP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral contraceptives will be taken daily for 24 days along with placebo (oral) once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabidiol + OCP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral contraceptives will be taken daily for 24 days along with Cannabidiol 400mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol Oil</intervention_name>
    <description>400 mg Cannabidiol oil will be administered daily along with oral contraceptives daily for 24 days.</description>
    <arm_group_label>Cannabidiol + OCP</arm_group_label>
    <other_name>Cannabidiol + OCP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered daily along with oral contraceptives daily for 24 days.</description>
    <arm_group_label>Placebo + OCP</arm_group_label>
    <other_name>Placebo + OCP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined oral contraceptive pill</intervention_name>
    <description>All participants will receive oral contraceptives</description>
    <arm_group_label>Cannabidiol + OCP</arm_group_label>
    <arm_group_label>Placebo + OCP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have regular menses (every 21-35 days)

          -  Not at risk for pregnancy (not sexually active, using a barrier method of birth
             control, using a copper IUD for birth control, have a partner with a vasectomy, have
             had a tubal ligation, or in a same sex relationship)

          -  Generally healthy women between the age of 18 to 35 years old

          -  English speaking

        Exclusion Criteria:

          -  Active users of hormonal contraception

               1. For combined methods, if they have recently stopped use, they must have had one
                  normal menstrual cycle

               2. For prior Depo-Medroxyprogesterone Acetate users, they must be off of the
                  medication for 2 months and be having regular menstrual cycles

          -  Pregnancy (less than 6 weeks prior), breastfeeding (less than 6 weeks prior),

             a. If participants have a normal menstrual cycle after these events, they may be
             considered for enrollment

          -  Any absolute/relative contraindications to EE and LNG (MEC category 3 or 4 [12])
             including impaired liver function, history of deep venous thrombosis, hypertension (&gt;
             140/90), diabetes with vascular changes, migraines with aura or neurological changes,
             history of myocardial infarction, pulmonary embolus, stroke or breast cancer.

          -  Use of CBD or THC products / Marijuana in the last 30 days

          -  Use of a known CYP450 inhibitor or inducer (other medication)

          -  BMI&gt;25

          -  Metabolic disorders including uncontrolled thyroid dysfunction and Polycystic Ovarian
             Syndrome

          -  Impaired liver or renal function

          -  Smoking/vaping/e-cigarettes

          -  Prior bariatric surgery

          -  Decisional impairment

          -  Incarceration
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Women's Health Research Unit Department of OB/Gyn</last_name>
      <phone>503-494-3666</phone>
      <email>whru@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shaalini Ramanadhan, MD</last_name>
      <email>ramanadh@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Shaalini Ramanadhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Shaalini Ramanadhan</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <keyword>Cannabidiol</keyword>
  <keyword>Combined oral contraceptives</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidiolex</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

